title: [Transesophageal atrial stimulation in the oral treatment of supraventricular reciprocal paroxysmal tachycardia in infants].
abstract: BACKGROUND
  The aim of the study was the evaluation of the usefulness of transesophageal atrial pacing in predicting chronic oral treatment efficacy of symptomatic reciprocating supraventricular tachycardia in infants and in avoiding the risk of very dangerous recurrences at home.
  
  
  METHODS
  We studied 13 infants (11 males, 2 females, mean age 43 +/- 31 days) with symptomatic reciprocating supraventricular tachycardia and no structural heart disease. All patients had chronic oral therapy, using the drug effective in acute i.v. somministration. Each patient was discharged when supraventricular tachycardia was not inducible with transesophageal atrial pacing after 5 half-lives of the drug used in chronic oral treatment. All patients, every 6 months, were retested with transesophageal atrial pacing alternatively during chronic oral therapy and after complete wash out. Oral therapy was stopped in each patient when supraventricular tachycardia was not inducible after the wash out.
  
  
  RESULTS
  The number of oral treatments tested for each patient were 2 +/- 1 (range 1-5). The number of transesophageal studies performed for each patient were 4 +/- 2 (range 3-7). No patient had symptomatic episodes of supraventricular tachycardia or needed to change therapy during the follow-up. The oral treatment was stopped after the twelfth month of life in 8 patients and after the twenty-fourth in 2 others without recurrences.
  
  
  CONCLUSIONS
  Transesophageal atrial pacing seems to be useful in predicting accurately and rapidly the oral treatment efficacy of supraventricular tachycardia in infants. Our protocol seems to be effective to avoid dangerous recurrences of tachycardia and to decide when we can stop therapy without risk.
authors.affiliation: Dipartimento Medico Chirurgico di Cardiologia Pediatrica, Ospedale Pediatrico Bambino Gesù, Roma.
authors.forename: F
authors.initials: F
authors.lastname: Drago
authors.forename: A
authors.initials: A
authors.lastname: Turchetta
authors.forename: P
authors.initials: P
authors.lastname: Guccione
authors.forename: A
authors.initials: A
authors.lastname: Santilli
authors.forename: E
authors.initials: E
authors.lastname: Pompei
authors.forename: M G
authors.initials: MG
authors.lastname: Gagliardi
authors.forename: A
authors.initials: A
authors.lastname: Calzolari
authors.forename: P
authors.initials: P
authors.lastname: Ragonese
mesh_terms: D000284:Administration, Oral; D000889:Anti-Arrhythmia Agents / Q000008:administration & dosage; D002304:Cardiac Pacing, Artificial / Q000379:methods*; D003131:Combined Modality Therapy; D004947:Esophagus; D005260:Female; D006325:Heart Atria; D006801:Humans; D007223:Infant; D007231:Infant, Newborn; D008297:Male; D010138:Pacemaker, Artificial; D012008:Recurrence; D013614:Tachycardia, Paroxysmal / Q000628:therapy*; D013617:Tachycardia, Supraventricular / Q000628:therapy*
chemical_list: D000889:Anti-Arrhythmia Agents
vernacular_title: La stimolazione atriale transesofagea nel trattamento orale della tachicardia parossistica reciprocante sopraventricolare del lattante.